X4 Pharmaceuticals, Inc. (XFOR)
Largest Insider Buys in Sector
XFOR Stock Price History Chart
XFOR Stock Performance
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Insider Activity of X4 Pharmaceuticals, Inc.
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $29,875 and sold $774,007 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $29,875 and sold $572,349 worth of stock each year.
Highest buying activity among insiders over the last 12 months: WYZGA MICHAEL S (director) — $89,625.
The last purchase of 25,000 shares for transaction amount of $29,875 was made by WYZGA MICHAEL S (director) on 2023‑08‑18.
List of Insider Buy and Sell Transactions, X4 Pharmaceuticals, Inc.
| 2024-03-11 | Sale | Ragan Paula | President and CEO | 49,678 0.0287% | $0.88 | $43,856 | +16.13% | |
| 2024-03-11 | Sale | DiBiase Mary | Chief Operating Officer | 15,409 0.0089% | $0.88 | $13,591 | +16.13% | |
| 2024-03-11 | Sale | Taveras Arthur | Chief Scientific Officer | 14,235 0.0082% | $0.88 | $12,552 | +16.13% | |
| 2024-03-11 | Sale | Mostafa Adam S. | Chief Financial Officer | 52,500 0.0304% | $0.88 | $46,347 | +16.13% | |
| 2024-02-12 | Sale | Ragan Paula | President and CEO | 21,695 0.0129% | $1.01 | $21,892 | -0.98% | |
| 2024-02-12 | Sale | DiBiase Mary | Chief Operating Officer | 3,683 0.0022% | $1.01 | $3,709 | -0.98% | |
| 2024-02-12 | Sale | Taveras Arthur | Chief Scientific Officer | 787 0.0005% | $1.01 | $793 | -0.98% | |
| 2024-02-12 | Sale | Mostafa Adam S. | Chief Financial Officer | 27,721 0.0165% | $1.01 | $27,973 | -0.98% | |
| 2023-11-03 | Sale | Ragan Paula | President and CEO | 39,906 0.0231% | $0.90 | $35,915 | -3.13% | |
| 2023-11-01 | Sale | Ragan Paula | President and CEO | 199,531 0.1172% | $0.73 | $145,658 | +21.92% | |
| 2023-11-01 | Sale | DiBiase Mary | Chief Operating Officer | 67,695 0.0398% | $0.73 | $49,417 | +21.92% | |
| 2023-11-01 | Sale | Taveras Arthur | Chief Scientific Officer | 67,695 0.0398% | $0.73 | $49,417 | +21.92% | |
| 2023-11-01 | Sale | Mostafa Adam S. | Chief Financial Officer | 230,645 0.1355% | $0.73 | $168,371 | +21.92% | |
| 2023-11-01 | Sale | Baldry Mark | Chief Commercial Officer | 10,257 0.006% | $0.73 | $7,488 | +21.92% | |
| 2023-09-08 | Sale | DiBiase Mary | Chief Operating Officer | 2,642 0.0016% | $1.25 | $3,300 | -24.32% | |
| 2023-08-18 | WYZGA MICHAEL S | director | 25,000 0.0162% | $1.20 | $29,875 | -18.70% | ||
| 2023-08-10 | Sale | Stewart Murray | Interim Chief Medical Officer | 130,056 0.0848% | $1.06 | $137,859 | -10.03% | |
| 2023-06-30 | Sale | DiBiase Mary | Chief Operating Officer | 464 0.0003% | $1.89 | $877 | -49.81% | |
| 2023-06-30 | Sale | Mostafa Adam S. | Chief Financial Officer | 2,641 0.0018% | $1.89 | $4,991 | -49.81% | |
| 2023-06-23 | Sale | Ragan Paula | President and CEO | 6,724 0.0045% | $1.92 | $12,910 | -50.05% |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $23.51M | 10.07 | 16.92M | 0% | +$0 | 2.36 | |
| Nea Management Company Llc | $20.83M | 8.92 | 14.99M | 0% | +$0 | 0.24 | |
| BlackRock | $12.14M | 5.2 | 8.74M | +3.78% | +$442,496.77 | <0.0001 | |
| The Vanguard Group | $10.88M | 4.66 | 7.83M | -2.26% | -$251,781.81 | <0.0001 | |
| OrbiMed | $9.92M | 4.25 | 7.13M | 0% | +$0 | 0.2 | |
| Soleus Capital Management, L.P. | $6.37M | 2.73 | 4.58M | New | +$6.37M | 0.06 | |
| Adage Capital Partners Gp L L C | $5.94M | 2.55 | 4.28M | 0% | +$0 | 0.01 | |
| Sio Capital Management LLC | $4.99M | 2.14 | 3.59M | 0% | +$0 | 1.76 | |
| Perceptive Advisors | $4.93M | 2.11 | 3.55M | 0% | +$0 | <0.01 | |
| Kingdon Capital Management | $4.83M | 2.07 | 3.47M | 0% | +$0 | 0.64 | |
| AXA | $4.27M | 1.83 | 3.07M | +0.03% | +$1,167.60 | 0.01 | |
| Geode Capital Management | $4.09M | 1.75 | 2.95M | +5.1% | +$198,758.68 | <0.0001 | |
| State Street | $3.51M | 1.5 | 2.52M | +3.94% | +$133,114.72 | <0.0001 | |
| Ensign Peak Advisors Inc | $3.39M | 1.45 | 2.44M | New | +$3.39M | 0.01 | |
| Avidity Partners Management Lp | $3.35M | 1.44 | 2.41M | New | +$3.35M | 0.12 | |
| Morgan Stanley | $1.95M | 0.84 | 1.41M | +250.4% | +$1.4M | <0.0001 | |
| Ubs Oconnor Llc | $1.86M | 0.8 | 1.34M | -23.38% | -$566,448.57 | 0.16 | |
| Goldman Sachs | $1.47M | 0.63 | 1.06M | +1,354.81% | +$1.37M | <0.0001 | |
| Northern Trust | $1.47M | 0.63 | 1.05M | -0.8% | -$11,810.83 | <0.0001 | |
| Schonfeld Group | $1.27M | 0.55 | 915,000 | +66.58% | +$508,323.00 | 0.01 | |
| Parkman Healthcare Partners Llc | $1.12M | 0.48 | 805,359 | +4.96% | +$52,857.53 | 0.14 | |
| Citadel Advisors LLC | $1.06M | 0.45 | 762,854 | -55.85% | -$1.34M | <0.01 | |
| Point72 Asset Management | $903,500.00 | 0.39 | 650,000 | 0% | +$0 | <0.01 | |
| Susquehanna International Group | $698,704.00 | 0.3 | 502,665 | +24.75% | +$138,644.09 | <0.01 | |
| Barclays | $623,000.00 | 0.27 | 448,708 | -15.27% | -$112,314.33 | <0.0001 | |
| Nuveen | $608,978.00 | 0.26 | 438,114 | 0% | +$0 | <0.0001 | |
| Simplify Asset Management Inc | $556,000.00 | 0.24 | 400,000 | 0% | +$0 | 0.05 | |
| ROYCE & ASSOCIATES INC | $475,885.00 | 0.2 | 342,363 | -11.85% | -$63,940.06 | <0.01 | |
| BNY Mellon | $467,004.00 | 0.2 | 335,974 | -2.88% | -$13,872.20 | <0.0001 | |
| New Leaf Venture Partners | $465,650.00 | 0.2 | 335,000 | 0% | +$0 | 0.41 | |
| Charles Schwab | $450,142.00 | 0.19 | 323,843 | 0% | +$0 | <0.0001 | |
| Gsa Capital Partners Llp | $446,000.00 | 0.19 | 321,021 | -66.04% | -$867,142.34 | 0.04 | |
| Millennium Management LLC | $359,675.00 | 0.15 | 258,759 | -84.45% | -$1.95M | <0.0001 | |
| RhumbLine Advisers | $227,135.00 | 0.1 | 163,415 | +1.9% | +$4,232.33 | <0.0001 | |
| UBS | $179,427.00 | 0.08 | 129,084 | +10,437.47% | +$177,724.25 | <0.0001 | |
| Citigroup | $176,601.00 | 0.08 | 127,051 | +620.65% | +$152,095.29 | <0.0001 | |
| Bank of America | $142,769.00 | 0.06 | 102,712 | -51.75% | -$153,143.91 | <0.0001 | |
| Invesco | $137,085.00 | 0.06 | 98,622 | +2.28% | +$3,052.45 | <0.0001 | |
| Stifel | $119,855.00 | 0.05 | 86,225 | -4.67% | -$5,875.64 | <0.0001 | |
| Amundi | $97,566.00 | 0.05 | 81,305 | 0% | +$0 | <0.0001 | |
| Jane Street Capital | $107,657.00 | 0.05 | 77,452 | -40.09% | -$72,031.72 | <0.0001 | |
| Lighthouse Investment Partners, LLC | $97,887.00 | 0.04 | 70,422 | New | +$97,887.00 | 0.01 | |
| American International Group | $85,812.00 | 0.04 | 61,735 | +0.88% | +$746.43 | <0.0001 | |
| Dimensional Fund Advisors | $76,861.00 | 0.03 | 55,296 | 0% | +$0 | <0.0001 | |
| Deutsche Bank | $73,376.00 | 0.03 | 52,789 | New | +$73,376.00 | <0.0001 | |
| New York State Common Retirement Fund | $72,000.00 | 0.03 | 51,551 | 0% | +$0 | <0.0001 | |
| JPMorgan Chase | $71,066.00 | 0.03 | 51,127 | -35.94% | -$39,862.12 | <0.0001 | |
| Walleye Capital | $66,126.00 | 0.03 | 47,573 | +60.63% | +$24,960.05 | <0.0001 | |
| AllianceBernstein | $63,495.00 | 0.03 | 45,680 | 0% | +$0 | <0.0001 | |
| Cibc Private Wealth Group Llc | $63,450.00 | 0.03 | 45,000 | 0% | +$0 | <0.0001 |